[ad_1]
JAKARTA: Indonesia’s state pharmaceutical company Bio Farma said on Tuesday that provisional data on the trials it was conducting with vaccines produced by the Chinese company Sinovac showed an efficacy of up to 97%.
“Our clinical trial team found, within a month, that interim data shows up to 97% efficacy,” Iwan Setiawan, spokesperson for Bio Farma, told a news conference.
He did not elaborate on whether the intermediate result was from a late-stage clinical trial, but another Bio Farma spokesperson later told Reuters that the company is still collecting data on the efficacy of the ongoing phase 3 trial.
Sinovac had previously said that 97% of healthy adults receiving lower doses who participated in its phase 1-2 trial showed an antibody-related immune response after taking its Covid-19 vaccine, CoronaVac.
A Sinovac spokesperson said Tuesday that the company had not received efficacy readings from phase 3 clinical trials.
The Brazilian Butantan Institute biomedical center, which is running a phase 3 trial of CoronaVac in the country, said last week that Sinovac was expected to publish the efficacy results of its vaccine trials by December 15.
Bio Farma did not provide data on how many participants were infected during the trial involving 1,600 people.
Iwan said Bio Farma would await full results and hoped that the Indonesian food and drug agency would issue an emergency use authorization in late January before mass vaccination could begin.
